Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 56

1.

Contemporary agents in the management of metastatic castration-resistant prostate cancer.

Kapoor A, Wu C, Shayegan B, Rybak AP.

Can Urol Assoc J. 2016 Nov-Dec;10(11-12):E414-E423. doi: 10.5489/cuaj.4112. Epub 2016 Dec 12. Review.

2.

First-line non-cytotoxic therapy in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a systematic review of 10 randomised clinical trials.

Poorthuis MHF, Vernooij RWM, van Moorselaar RJA, de Reijke TM.

BJU Int. 2017 Jun;119(6):831-845. doi: 10.1111/bju.13764. Epub 2017 Feb 28. Review.

PMID:
28063195
3.

Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis.

Yi R, Chen B, Duan P, Zheng C, Shen H, Liu Q, Yuan C, Ou W, Zhou Z.

J Immunol Res. 2016;2016:4543861. doi: 10.1155/2016/4543861. Epub 2016 Dec 12. Review.

4.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.

McNeel DG, Bander NH, Beer TM, Drake CG, Fong L, Harrelson S, Kantoff PW, Madan RA, Oh WK, Peace DJ, Petrylak DP, Porterfield H, Sartor O, Shore ND, Slovin SF, Stein MN, Vieweg J, Gulley JL.

J Immunother Cancer. 2016 Dec 20;4:92. doi: 10.1186/s40425-016-0198-x. eCollection 2016.

5.

Understanding the role of new systemic agents in the treatment of prostate cancer.

Corfield J, Crozier J, Joshua AM, Bolton D, Lawrentschuk N.

BJU Int. 2016 Oct;118 Suppl 3:8-13. doi: 10.1111/bju.13633. Epub 2016 Oct 6. Review.

PMID:
27709828
6.

Therapeutic management of bone metastasis in prostate cancer: an update.

Zustovich F, Pastorelli D.

Expert Rev Anticancer Ther. 2016 Oct 6:1-13. [Epub ahead of print]

PMID:
27666299
7.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.

Eur Urol. 2017 Apr;71(4):630-642. doi: 10.1016/j.eururo.2016.08.002. Epub 2016 Aug 31.

PMID:
27591931
8.

[Immunotherapy in the treatment of genitourinary cancers].

Géczi L, Ladányi A, Vajdics T, Küronya Z, Bíró K, Gyergyay F, Martin T, Nagyiványi K.

Magy Onkol. 2016 Mar 2;60(1):41-5. Epub 2016 Feb 8. Hungarian.

9.

Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science.

Nussbaum N, George DJ, Abernethy AP, Dolan CM, Oestreicher N, Flanders S, Dorff TB.

Prostate Cancer Prostatic Dis. 2016 Jun;19(2):111-21. doi: 10.1038/pcan.2015.42. Epub 2016 Feb 2. Review.

10.

Singapore Cancer Network (SCAN) Guidelines for the Management of Advanced Castrate-Resistant Prostate Cancer.

Singapore Cancer Network (SCAN) Genitourinary Cancer Workgroup.

Ann Acad Med Singapore. 2015 Oct;44(10):397-405.

11.

Systemic Medical Treatment in Men with Metastatic Castration-Resistant Prostate Cancer: Recommendations for Daily Routine.

Herden J, Heidegger I, Paffenholz P, Porres D.

Oncol Res Treat. 2015;38(12):654-68. doi: 10.1159/000442030. Epub 2015 Nov 23. Review.

PMID:
26633646
12.

[Treatment strategies for advanced prostate cancer].

Küronya Z, Bíró K, Géczi L, Németh H.

Magy Onkol. 2015 Sep;59(3):229-40. Epub 2015 May 26. Review. Hungarian.

13.

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy.

Mulders PF, De Santis M, Powles T, Fizazi K.

Cancer Immunol Immunother. 2015 Jun;64(6):655-63. doi: 10.1007/s00262-015-1707-3. Epub 2015 May 30. Review.

14.

Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective.

Simpson EL, Davis S, Thokala P, Breeze PR, Bryden P, Wong R.

Pharmacoeconomics. 2015 Nov;33(11):1187-94. doi: 10.1007/s40273-015-0296-5. Review.

PMID:
26017401
15.

Outcomes of Sipuleucel-T Therapy [Internet].

Mark D, Samson DJ, Bonnell CJ, Ziegler KM, Aronson N.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2011 Feb 10.

16.

Corticosteroids in the management of prostate cancer: a critical review.

Ndibe C, Wang CG, Sonpavde G.

Curr Treat Options Oncol. 2015 Feb;16(2):6. doi: 10.1007/s11864-014-0320-6. Review.

PMID:
25762121
17.

Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy.

Graff JN, Chamberlain ED.

Core Evid. 2014 Dec 18;10:1-10. doi: 10.2147/CE.S54712. eCollection 2015. Review.

18.

Economic evaluation of therapeutic cancer vaccines and immunotherapy: a systematic review.

Geynisman DM, Chien CR, Smieliauskas F, Shen C, Shih YC.

Hum Vaccin Immunother. 2014;10(11):3415-24. doi: 10.4161/hv.29407. Review.

19.

SEOM clinical guidelines for the treatment of metastatic prostate cancer.

Cassinello J, Climent MA, González del Alba A, Mellado B, Virizuela JA; Spanish Society for Medical Oncology.

Clin Transl Oncol. 2014 Dec;16(12):1060-6. doi: 10.1007/s12094-014-1225-3. Epub 2014 Oct 16.

20.

[Current treatment concepts for castration resistant prostate cancer].

von Amsberg G, Stroelin P, Bokemeyer C, Steuber T.

Dtsch Med Wochenschr. 2014 Oct;139(41):2086-90. doi: 10.1055/s-0034-1387276. Epub 2014 Sep 30. Review. German. Erratum in: Dtsch Med Wochenschr. 2014 Dec;139(50):2563.

PMID:
25268211

Supplemental Content

Loading ...
Support Center